In the pharmaceutical industry, Ofloxacin 200 mg is a highly effective, second-generation fluoroquinolone antibiotic. As a pharmacist and manufacturer, I view Ofloxacin as a versatile “broad-spectrum” agent, capable of treating a wide array of infections by targeting both Gram-positive and Gram-negative bacteria.

Its excellent tissue penetration and high oral bioavailability make it a staple in global pharmaceutical trade.

Primary Clinical Uses

• Urinary Tract Infections (UTIs): Highly effective against complicated and uncomplicated UTIs caused by E. coli and other pathogens.

• Respiratory Tract Infections: Used for acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia.

• Skin and Soft Tissue Infections: Treatment of uncomplicated infections of the skin.

• Sexually Transmitted Infections (STIs): Effective against uncomplicated gonorrhea and chlamydia.

• Prostatitis: Due to its superior ability to penetrate the prostate gland.

• Bacterial Diarrhea: Frequently used in international markets for travel-related infections and enteric fever (Typhoid).

Mechanism of Action: Inhibiting DNA Replication

Ofloxacin is bactericidal, meaning it kills bacteria directly by interfering with their genetic processes.

Enzyme Targeting: It inhibits two essential bacterial enzymes: DNA Gyrase (in Gram-negative bacteria) and Topoisomerase IV (in Gram-positive bacteria).

Supercoiling Interference: These enzymes are responsible for the uncoiling and re-coiling of DNA during replication.

Lethal DNA Damage: By blocking these enzymes, Ofloxacin prevents the bacteria from repairing or copying their DNA, leading to rapid cell death.

The Manufacturer’s Perspective: Formulation & Export

From a production and global trade standpoint at our WHO-GMP facility, Ofloxacin 200 mg requires specific technical considerations:

• Bioavailability (USP): Ofloxacin has nearly 95% bioavailability, meaning the oral dose is almost equivalent to an intravenous dose. This makes it a cost-effective alternative for B2B buyers looking for hospital-grade performance in tablet form.

• Cation Interactions: As a manufacturer, we must ensure the Product Information Leaflet (PIL) warns patients not to take Ofloxacin with antacids (Aluminum/Magnesium) or iron supplements, as these can form “chelates” that prevent the drug from being absorbed.

• Stability for Tropical Export: Ofloxacin is relatively stable but light-sensitive. We utilize opaque PVC/PVDC or Alu-Alu blister packaging to ensure a 36-month shelf life for export to Zone IVb regions.

• Dossier Support: This is a high-volume product for international healthcare tenders. Our Mumbai-based facility provides full CTD/eCTD Dossiers to support your firm’s registration and supply goals.